Comp in-vitro disso studies for generics in India [Dissolution / BCS / IVIVC]

posted by jag009  – NJ, 2020-03-12 16:41 (1061 d 22:37 ago) – Posting: # 21259
Views: 4,601

Hi everyone,

I have question relating to ANDA in India (CDSCO). With US ANDA, we have the FDA recommended dissolution method for a marketed drug which the generic company needs to carry out the Test vs Ref in-vitro with (if the method is not doable for some reason then the company must justify they have to use another meothod). Does this exist in India? If not then, what's the approach for India ANDA (I mean aside from developing your own method for your product and compare against the ref).

Reference article link, if available, would be greatly appreciated.

Thx
J

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
17 visitors (0 registered, 17 guests [including 9 identified bots]).
Forum time: 15:19 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5